ANI Pharmaceuticals Inc (ANIP) Stock Forecast & Price Target
ANI Pharmaceuticals Inc · NASDAQ
$80.97+2.60 (+3.32%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering ANI Pharmaceuticals Inc, 4 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $90.00 to $124.00, so the covering firms are broadly aligned. The average target of $106.83 sits 32% above the current $80.97. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 27% this year and 11% next, consensus EPS building from about $2.51 next quarter toward $10.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy467%
Hold233%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to ANI Pharmaceuticals Inc.
As of Jul, 4 of 6 firms rate ANIP a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANIP EPS & revenue forecast
EPS · NEXT QUARTER
$2.51
Range $2.28 – $2.80 · 8 analysts · +23% YoY
Next period, 8 analysts expect ANI Pharmaceuticals Inc to earn $2.51 a share (range $2.28 – $2.80), versus $2.04 a year earlier. Full-year consensus is $9.42, growing to $10.76 the year after.
REVENUE · NEXT QUARTER
$297.3M
Range $290.0M – $310.2M · 8 analysts · +31% YoY
Revenue is expected to reach $297.3M (range $290.0M – $310.2M), +31.0% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering ANI Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANIP.
#1
David Amsellem
Piper Sandler · Rank #95
Buy
$111.00+37.1% to target
Overall win rate
50%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$94.00+16.1% to target
Overall win rate
54%
+ Follow
#3
Elliot Wilbur
Raymond James · Rank #234
Buy
$83.00+2.5% to target
Overall win rate
32%
+ Follow
#4
Vamil Divan
Guggenheim
Buy
$124.00+53.1% to target
Coverage
—
+ Follow
#5
GF
Gregory Fraser
Truist Securities
Hold
$90.00+11.2% to target
Coverage
—
+ Follow
ANIP stock forecast FAQ
What is ANIP's average 12-month price target?+
The 6 analysts with a live target average $106.83 for ANI Pharmaceuticals Inc over the next 12 months, ranging from a $124.00 high to a $90.00 low.
Is ANIP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 4 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ANIP?+
The Street-high target is $124.00 (Guggenheim), and the Street-low is $90.00 (Truist Securities). The average of all 6 active targets is $106.83.
How many Wall Street analysts cover ANIP?+
6 analysts have an active rating on ANI Pharmaceuticals Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANIP?+
Among analysts who currently cover ANIP, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Buy with a $111.00 target.
What is ANI Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $2.51 per share (range $2.28 – $2.80) across 8 analysts. Full-year EPS is projected at $9.42, rising to $10.76 the following year.
How much revenue is ANI Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $297.3M (range $290.0M – $310.2M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading ANIP lately?+
As of Jul, 4 of 6 firms rate ANIP a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANIP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
